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Summary
 
Members of the tumor necrosis factor (TNF) family induce pleiotropic biological responses, in-
cluding cell growth, differentiation, and even death. Here we describe a novel member of the
TNF family designated APRIL (for a proliferation-inducing ligand). Although transcripts of
APRIL are of low abundance in normal tissues, high levels of mRNA are detected in trans-
formed cell lines, and in human cancers of colon, thyroid, and lymphoid tissues in vivo. The
addition of recombinant APRIL to various tumor cells stimulates their proliferation. Moreover,
APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice com-
pared with the parental cell line. These findings suggest that APRIL may be implicated in the
regulation of tumor cell growth.
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M
 
embers of the TNF cytokine family are critically in-
volved in the regulation of infections, inflammation,
autoimmune diseases, and tissue homeostasis (1). These
ligands can act in a membrane-bound form or as proteoly-
tically processed, soluble cytokines in an autocrine, para-
crine, or endocrine manner (1). Binding to their respective
receptors leads to the triggering of diverse signaling path-
ways, including the activation of caspases, the translocation
of nuclear factor-
 
k
 
B (NF-
 
k
 
B), or the activation of mito-
gen-activated kinases such as c-Jun NH
 
2
 
-terminal kinase
(JNK) or extracellular signal–regulatory kinase (ERK).
Thus, TNF-related ligands can lead to either apoptosis, dif-
ferentiation, or proliferation (1). To date, 13 members of
the TNF cytokine family have been described: TNF-
 
a
 
, lym-
photoxin (LT)
 
a
 
, LT
 
b
 
, CD40L, CD30L, CD27L, 4-1BBL,
OX40L, FasL, TRAIL/APO-2L (2, 3), TRANCE/
RANKL (4, 5), LIGHT (6), and TWEAK (7).
The ligand members are type II membrane molecules.
Their extracellular domains have 
 
b
 
 jelly roll topography
(8), and are important in ligand trimerization. Intrinsic to
oligomerization is the formation of the receptor binding
site at the junction between neighboring subunits, creating
a multivalent ligand. The binding of the ligands to their re-
spective receptors induces oligomerization, initiating down-
stream signaling events.
Here we characterize the structural and functional prop-
erties of a new ligand of the TNF cytokine family. The
new ligand, termed APRIL (for a proliferation-inducing
ligand), is primarily expressed in tumor tissues and can ac-
celerate the growth of transformed cells in vitro and in
vivo.
 
Materials and Methods
 
Materials.
 
The anti-FLAG M2 mAb and the anti-FLAG M2
antibody coupled to agarose were purchased from Eastman
Kodak Co. (Rochester, NY). Protein A–Sepharose and CNBr-
activated Sepharose were purchased from Amersham Pharmacia
Biotech (Uppsala, Sweden). Cell culture reagents were obtained
from Life Sciences (Basel, Switzerland). Human TWEAK cDNA
was provided by Dr. J. Browning (Biogen, Inc., Cambridge,
MA). FLAG-tagged soluble human TWEAK (residues 141–284)
and FLAG-tagged soluble FasL were produced in 293 cells as de-
scribed (9, 10).
 
Cells.
 
Murine B lymphoma A20 and human embryonic kid-
ney cells 293 T (11) were maintained in DMEM containing 10%
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heat-inactivated FCS. The human T lymphoblastoma Jurkat cells,
colon adenocarcinoma HT-29 cells, Raji Burkitt lymphoma, and
human MCF-7 cells were grown in RPMI supplemented with
10% FCS. All media contained antibiotics (penicillin and strepto-
mycin at 5 
 
m
 
g/ml each and neomycin at 10 
 
m
 
g/ml). Other cell
lines referred to in this paper are deposited in and described by
the American Type Culture Collection (Rockville, MD).
 
Northern Blot Analysis and In Situ Hybridization.
 
Northern blot
analysis was carried out using the following membranes: human
multiple tissue Northern blots I and II (7760-1 and 7759-1;
Clontech, Palo Alto, CA), human cancer cell line MTN blot
(7757-1; Clontech), and human tumor panel blot V (D3500-01;
Invitrogen Corp., Carlsbad, CA). The membranes were incu-
bated in ExpressHyb hybridization solution (8015-1; Clontech)
for at least 1 h at 62
 
8
 
C. The random-primed cDNA probe (Boeh-
ringer Mannheim Corp., Indianapolis, IN) was synthesized using
cDNA corresponding to the extracellular domain of APRIL as
template. The heat-denatured cDNA probe was added at 1.5 
 
3 
 
10
 
6
 
cpm/ml in fresh ExpressHyb. The membrane was hybridized 12–
24 h at 62
 
8
 
C, washed three times in 2
 
3
 
 SSC containing 0.05%
SDS, and exposed at 
 
2
 
70
 
8
 
C to x-ray films.
For in situ hybridization, cryostat sections (6–8 
 
m
 
m) of primary
colon carcinomas (three patients) were air dried, fixed in 4% (wt/
vol) paraformaldehyde in PBS, and used immediately for immuno-
fluorescence or stored in 70% ethanol at 4
 
8
 
C before in situ hy-
bridization. In situ hybridization and immunofluorescence were
performed as reported previously (12). After in situ hybridization,
slides were directly exposed to x-ray films. Specificity controls in-
cluded the systematic use of sense cRNA probes in each experi-
ment.
 
Characterization of APRIL cDNA and Expression of Recombinant
Soluble APRIL.
 
The full-length APRIL gene (sequence data
available from EMBL/GenBank/DDBJ under accession no.
AF046888) was contained in the expressed sequence tag (EST)
clones AA292304 and AA292358. EST clone AA292304 was used
to amplify the coding region of APRIL using a specific 5
 
9
 
 for-
ward primer flanked by an EcoRI site (5
 
9
 
-CCAGCCTCATCT-
CCTTTCTTGC-3
 
9
 
) and a specific 3
 
9
 
 reverse primer flanked by
an XbaI site (5
 
9
 
-TCACAGTTTCACAAACCCCAGG-3
 
9
 
). The
amplified fragment was cut with EcoRI/XbaI and cloned into a
modified version of pCRIII (Invitrogen Corp.), in frame with an
NH
 
2
 
-terminal FLAG peptide (9). The soluble form of APRIL
(sAPRIL) was generated using the two primers 5
 
9
 
-AAACAGAA-
GAAGCAGCACTCTG-3
 
9
 
 and 5
 
9
 
-TCACAGTTTCACAAAC-
CCCAGG-3
 
9
 
 containing a PstI and XbaI site, respectively, and
subsequently cloned into a modified pCRIII vector containing
both a hemagglutinin signal for protein secretion in eukaryotic
cells and an NH
 
2
 
-terminal FLAG epitope (9). Purification of
FLAG-tagged APRIL was affinity-purified on anti-FLAG M2 an-
tibody coupled to agarose.
 
Proliferation Assays.
 
The proliferation of cells was determined
by incubating 5 
 
3 
 
10
 
4
 
 cells/well in 100 
 
m
 
l medium with the in-
dicated concentrations of recombinant sAPRIL, sTWEAK, and
sFasL using the Celltiter 96 AQ proliferation assay (Promega
Corp., Madison, WI) after 24 h, following the manufacturer’s in-
structions. Alternatively, cells were pulsed for 4 h with [
 
3
 
H]thy-
midine (0.5 
 
m
 
Ci/well), exposed to three cycles of freezing and
thawing, and harvested. [
 
3
 
H]Thymidine incorporation was moni-
tored by liquid scintillation counting. For the immunodepletion
of FLAG-APRIL, anti-FLAG antibodies coupled to agarose
(Eastman Kodak Co.) were used.
 
Cell Lines Stably Expressing APRIL.
 
The full-length FLAG-
tagged APRIL containing pCRIII expression vector was trans-
fected into NIH-3T3 cells using the calcium phosphate method
of transfection. 48 h after transfection, cells were seeded at 10
 
4
 
cells/well in flat-bottomed 96-well plates under selection with
800 
 
m
 
g/ml G418 (Sigma Chemical Co., St. Louis, MO). Cell ex-
tracts of stable clones were electrophoretically separated by SDS-
PAGE under reducing conditions and subsequently transferred
to nitrocellulose. Immunoblots of FLAG-tagged APRIL were
probed using 5 
 
m
 
g/ml of anti-FLAG M2 mAb and the ECL sys-
tem (Amersham Pharmacia Biotech).
 
Tumor Growth in Mice.
 
NIH-3T3 fibroblasts (American Type
Culture Collection) and the various transfectants (10
 
5 
 
cells) were
suspended in 50 
 
m
 
l PBS and injected subcutaneously into the
flank region of BALB/c nude mice (Harlan Nederland, Zeist,
The Netherlands). Mice were sex- and age-matched.
 
Results and Discussion
 
APRIL Is a Novel Ligand of the TNF Family.
 
All TNF
ligand/receptor family members characterized to date are
biologically important. Therefore, we screened public data-
bases using an improved profile search (13) based on an op-
timal alignment of all currently known TNF ligand family
members. Several candidate clones were found coding for a
unique, novel TNF-
 
a
 
–related ligand which we termed
APRIL (for a proliferation-inducing ligand). Two of these
cDNA clones (AA292358 and AA292304) contained full-
length sequences (1.5 and 1.7 kb, respectively) encoding a
protein of 250 amino acids, with a predicted cytoplasmic
domain of 28 amino acids, a hydrophobic transmembrane
region, and an extracellular domain of 201 amino acids
(Fig. 1 
 
A
 
). The absence of a signal peptide suggested that
APRIL was a type II membrane protein which is typical of
the members of the TNF ligand family. The single N-linked
glycosylation site (N124) predicted for this protein lies
within the first of several 
 
b
 
 strands which are folded into an
antiparallel 
 
b
 
 sandwich structure (14). The sequence of the
extracellular domain of APRIL showed highest homology
with FasL (21% amino acid identity), TNF-
 
a
 
 (20%), and LT
 
b
 
(18%), followed by TRAIL, TWEAK, and TRANCE
(15%) (Fig. 1 
 
B
 
).
 
Expression of APRIL mRNA in Tumors.
 
Northern blot
analysis of APRIL revealed that the expression of APRIL
was weak and restricted only to a few tissues (Fig. 2 
 
A
 
).
Two transcripts of 2.1 and 2.4 kb were found in the pros-
tate, whereas a shorter 1.8-kb transcript was found in PBLs.
A longer exposure time of the Northern blot revealed that
the 2.1-kb APRIL mRNA was also present in colon,
spleen, and pancreas (data not shown). This restricted dis-
tribution of the APRIL mRNA was consistent with the or-
igin of cDNA clones currently available in the EST data-
base. Of the 23 clones identified, only two were derived
from normal tissues (pregnant uterus and pancreatic islet
cells). Remarkably, the remainder of the EST clones (21
clones, 91%) were present in cDNA libraries generated
from tumors or tumor-derived cell lines (ovary tumor, 11;
prostate tumor, 3; Gessler Wilms tumor, 1; colon carci-
noma, 1; endometrial tumor, 1; parathyroid tumors, 1;
pancreas tumor, 1; T cell lymphoma, 1; LNCAP adenocar-
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cinoma–derived cell line, 1). This is in contrast to TNF-
 
a
 
,
where only 16% of EST clones were tumor-derived. This
prompted us to test transformed cell lines for the expression
of APRIL mRNA (Fig. 2 
 
B
 
), and indeed, all tumor cell
lines strongly expressed the 2.1-kb transcript of APRIL.
The highest APRIL-specific signals were detected in the
colorectal adenocarcinoma SW480, the Burkitt’s lymphoma
Raji, and the melanoma G361 cell lines.
To corroborate this finding, we measured APRIL
mRNA expression levels in several tumors and compared
them to normal tissues. APRIL mRNA was elevated in
thyroid carcinoma and in lymphoma, whereas in the corre-
sponding normal tissues, hybridization signals were either
weak or absent (Fig. 2 
 
C
 
). In the two other tumors ana-
lyzed by Northern blots (adrenal and parotid carcinoma),
APRIL mRNA was not increased. By in situ hybridization,
highly increased levels of APRIL mRNA were also de-
tected in human colon adenocarcinomas of three different
patients compared with normal colon tissue (Fig. 2 
 
D
 
).
 
APRIL Enhances Tumor Cell Proliferation.
 
To explore the
possible activities of APRIL, we expressed a FLAG-tagged
form of the soluble extracellular domain of APRIL
(sAPRIL) encompassing amino acids 110–250 in 293 cells.
The widespread expression of APRIL in tumor cells and
tissues suggested to us that APRIL may be associated with
tumor growth, and we therefore incubated various tumor
Figure 1. (A) Predicted amino acid sequence of human APRIL. The predicted transmembrane region (TM, boxed), the potential N-linked glycosylation
site (*), and the NH2 terminus of the recombinant sAPRIL are indicated. (B) Comparison of the extracellular protein sequence of APRIL and some mem-
bers of the TNF ligand family. Identical and homologous residues are represented in black and shaded boxes, respectively. TNFa, TNF-a; LTa, LTa.
Figure 2. Expression of
APRIL. (A) Northern blots (2 mg
polyA1 RNA/lane) of various
human tissues were probed with
APRIL cDNA. (B) APRIL
mRNA expression in various
tumor cell lines: promyelocytic
leukemia HL60; HeLa cell S3;
chronic myelogenous leukemia
K562; lymphoblastic leukemia
Molt-4; Raji Burkitt’s lymphoma;
colorectal adenocarcinoma SW-
480; lung carcinoma A459; mela-
noma and G361. (C) APRIL
mRNA expression in four differ-
ent human tumors (T) and normal
tissues (N). The 18S rRNA band
shows equal loading. (D) APRIL
mRNA expression in primary co-
lon carcinoma. In situ hybridiza-
tion reveals abundant APRIL
message in human colon carci-
noma. Colon tumor tissue sec-
tions and adjacent normal colon
tissue were hybridized to antisense
APRIL 35S-labeled cRNA, and as
control, colon tumor tissue sec-
tions were also hybridized to sense
APRIL 35S cRNA (negative con-
trol). Top, Dark field micrographs;
bottom, the corresponding light
field micrographs.
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cell lines with purified recombinant sAPRIL. An increase in
proliferation of the Jurkat T lymphoma cells in the presence
of APRIL was observed in a dose-dependent manner as de-
tected by an increase in the number (z50%) of viable cells
24 h after ligand addition (Fig. 3 A). As expected, the addi-
tion of identically produced and purified FasL to Jurkat cells
decreased the number of viable cells, whereas TWEAK had
no effect. The increased cell number correlated with aug-
mented (40%) [3H]thymidine incorporation in APRIL-
treated cells (Fig. 3 A). Differences in growth rates of Jurkat
cells exposed to APRIL and TWEAK were already apparent
after 12 h of incubation, and after 36 h the number of Jurkat
cells had almost doubled (Fig. 3 A, right). Immunodepletion
of FLAG-tagged APRIL–containing medium by anti-FLAG
antibodies, but not anti-myc antibodies, reduced the prolif-
erative effect (Fig. 3 C), indicating that the stimulation of
proliferation was specific and due to the presence of APRIL.
Increased rates in proliferation were also seen in some B
lymphomas (human Raji cells, mouse A20 cells, but not hu-
man BJAB cells) and in cell lines of epithelial origin, such as
COS and HeLa, as well as melanomas (Fig. 3 B). The breast
carcinoma cell MCF-7 did not respond. The effect on Jurkat
cells was even more intense when the concentration of FCS
was reduced from 10 to 1% (Fig. 3 D).
Tumor Cells Expressing APRIL Display an Increased Growth
Rate in Mice. We next transfected NIH-3T3 cells with
full-length human APRIL and obtained several APRIL-
expressing clones (Fig. 4 A). Interestingly, APRIL transfec-
tants proliferated faster than mock-transfected cells or wild-
type cells (Fig. 4 B). Consequently, we asked the question
whether the APRIL-transfected NIH-3T3 cells might also
have a growth advantage in vivo. When wild-type or
mock-transfected NIH-3T3 cells were injected into nude
mice, small palpable tumors were observed after 5–6 wk. In
contrast, the two clones of NIH-3T3 cells stably transfected
with APRIL which were injected into nude mice both in-
duced tumors after only 3–4 wk. After 6 wk, mice had to
be killed due to the high tumor burden (Fig. 4 C).
Many of the TNF-related ligands can induce pleiotropic
biological responses. Ligands trigger costimulatory signals
in most cases, induce cell death, or lead to proliferation of
primary cells. For instance, TNF-R2 triggering leads to
proliferation of thymocytes (15), and the biological func-
tion of CD40-40L provides a clear example of costimula-
tion (14). TNF-a was discovered as a cytokine with the ca-
pacity to induce tumor necrosis (16). Unlike these ligands,
APRIL can stimulate the growth of tumor cell lines.
APRIL also appears to be unique among the TNF family,
as it is abundantly expressed in tumor cells. Collectively,
these results suggest that the physiological function(s) of
APRIL is distinct from other members of the TNF family.
Preliminary results indicate that the APRIL gene is not
linked to the TNF/LT locus in the MHC.
The mechanism by which APRIL increases cellular pro-
liferation of transformed cells is currently unknown. APRIL
does not appear to activate NF-kB or c-Jun NH2-terminal
Figure 3. APRIL stimulates cell growth. (A) Dose-dependent stimulation of proliferation of Jurkat cells (human leukemic T cells), determined 24 h after
the addition of sAPRIL. Controls include cells treated with FasL, TWEAK, and no ligand (Control). Left, Number of viable cells; middle, [3H]thymidine in-
corporation; right, kinetic analysis of the effect of APRIL on Jurkat cells. The concentrations of ligands are indicated. (B) Effect of APRIL on the proliferation
rate of Raji (human Burkitt lymphoma), A20 (mouse B lymphoma), BJAB (human B lymphoma), COS (SV40-transformed monkey kidney cells), MCF-7
(human breast adenocarcinoma), HeLa (human embryonic lung) cell, and ME260 (human melanoma). (C) Influence of immunodepletion of FLAG-tagged
APRIL on tumor cell growth. The proliferative effect of FLAG-tagged APRIL is neutralized by Sepharose-bound anti-FLAG antibodies, but not by anti-
myc antibodies. (D) Influence of FCS concentration on APRIL-induced proliferation of Jurkat cells. Data are the means 6 SEM of triplicate determinations.
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kinase, and the cell cycle analysis of APRIL-treated cells re-
mains unperturbed (data not shown). Moreover, the his-
tochemical analysis of tumors induced by APRIL-transfected
NIH-3T3 cells did not reveal any apparent morphological
differences compared with wild-type NIH-3T3 tumors, sug-
gesting that APRIL is not angiogenic. Thus, it will be im-
portant to identify and characterize the receptor for APRIL
(recombinant sAPRIL does not interact with Fas, LTbR,
HVEM, TNF-R1, TNF-R2, GITR, TRAIL-R1, TRAIL-
R2, or TRAIL-R3; data not shown).
The development of cancer is viewed as a multistep pro-
cess, involving mutation and selection for cells with pro-
gressively increasing capacity for proliferation, survival, and
invasion, even under conditions where the growth factor
(blood) supply is limited. APRIL allows tumor cells to pro-
liferate at a reasonable rate even in low serum conditions
(see Fig. 3 D). Given that APRIL is strongly expressed in
several types of tumors and that it stimulates cell prolifera-
tion in vitro and in vivo, it is possible that APRIL may play
a role in tumorigenesis. Therefore, antagonistic antibodies
to APRIL or the APRIL receptor may have a potential for
cancer treatment.
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